Ø Professor Teh elected to the Society for his outstanding records of scholarly achievement in biomedical research

Singapore, 24 April 2014
– Prof Teh Bin Tean, Director and Principal Investigator for the Laboratory of Cancer Epigenome, of the National Cancer Centre Singapore (NCCS) has been honoured for his clinical research works by being elected as a member of the American Society of Clinical Investigation (ASCI).

Prof Teh, who is a recipient of the Singapore Translational Research (STaR) Investigator Award, is amongst the 6 new members elected into the society this year. The ASCI is one of America’s oldest and most respected "honor society of physician-scientists, those who translate findings in the laboratory to the advancement of clinical practice".1

The ASCI comprises more than 3,000 physician-scientists from all medical specialties who are elected to the society for their significant research accomplishments. While the nominations of several hundred physician-scientists are being considered, a maximum of only 80 new members are elected each year.

Prof Teh was elected at his first nomination for his work done over the years in kidney cancer and Asian cancer genomics. He was nominated by Dr David M. Virshup, from Duke-NUS Graduate Medical School Singapore. In the nomination he described Prof Teh as "an international leader in kidney (RCC) and Asian cancer genomics."

Prof Teh's laboratory was the first to publish gene expression profiling of different kidney cancer types including the first renal cell carcinoma (RCC) prognostication paper based on gene expression profiling. Prof Teh and his team was also the first to discover the mechanism of action and resistance of Sunitinib, the most commonly used cancer drug as first line therapy for RCC. In Asian cancers, his group, in collaboration with Professors Patrick Tan and Steven Rozen from Duke-NUS Graduate Medical School, in Singapore was first to establish the mutational landscape of bile duct cancer and they are currently taking the lead on the International Cancer Genome Consortium (ICGC) biliary tract cancer genome project, putting Singapore on the map in this major cancer genomic consortium.

From 1990 to 2013, Prof Teh has published over 300 papers, many of which have been published in high impact scientific journals2 such as Cancer Cell, Cancer Discovery, Nature, Nature Genetics, Science Translational Medicine and many more. His most significant publications in Asian cancers include a recent publication in Science Translational Medicine on the identification of the molecular fingerprint of a natural compound known as Aristolochic acid found in Aristolochia plants – a plant used in herbal remedies for weight loss and treatment of ailments such as arthritis and menstrual cramps. This discovery not only enhances understanding of the molecular mechanism of this carcinogen, but also allows researchers to detect the involvement of this carcinogen in other cancer types such as liver cancer. This discovery is important as it drives the need to develop effective “toxicity” detection tools for herbal medicine.

The 76 new members will be officially welcomed into the ASCI at its annual ASCI Dinner and New Member Induction Ceremony on 25 April 2014 in Chicago, US.

1 ASCI website

2 The impact factor of an academic journal is a measure reflecting the average number of citations to recent articles published in the journal. The impact factor is often used as a measure on the importance of a journal within its field. Journals with higher impact factors deemed to be more important than those with lower o

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
About Professor Teh Bin Tean, M.D., Ph.D
Professor Teh obtained his medical degree (1992) from the University of Queensland, Australia and his Ph.D. (1997) from the Karolinska Institute, Sweden. Following postdoctoral work in multiple endocrine neoplasia 1 at Karolinska Institute, Dr Teh joined the Van Andel Research Institute (VARI, USA) as a Senior Scientific Investigator in the Laboratory of Cancer Genetics since January 2000. He moved to join National Cancer Centre Singapore as a Singapore Translational Research (STaR) Investigator in 2010. Currently, he is also Professor of Duke-NUS Graduate Medical School; and Senior Scientific Investigator, Cancer Science Institute of Singapore. He also holds Adjunct Professorships at Universities/Institutes in Sweden, USA, and China. Additionally, Dr. Teh has published extensively over 300 publications in high impact scientific journals and has been present and past member of various Editorial Boards such as Lancet Oncology, Cancer Research, International Journal of Oncology, the Journal of Endocrine Genetics, the Journal of Clinical Endocrinology and Metabolism, Clinical Genitourinary Cancer, and the American Journal of Translational Research.

About the National Cancer Centre Singapore
National Cancer Centre Singapore (NCCS) provides a holistic and multidisciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety.
In order to deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which have been internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
For further information, please contact NCCS Corporate Communications Department:
Ms Siti Zawiyah

Tel: 62369429